Anika Therapeutics (ANIK) Depreciation & Amortization (CF) (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1.4 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.4 million, up 1.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (down 17.4% YoY), and the FY2025 annual result was $5.4 million, down 21.96% from the prior year.
• Depreciation & Amortization (CF) rose to $1.4 million in Q1 2026 per ANIK's latest filing, from $1.3 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q3 2024 and troughed at $1.3 million in Q2 2025.
• A 5-year average of $1.6 million and a median of $1.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) rose 16.54% in 2024, then decreased 26.01% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.7 million in 2022, then decreased by 5.35% to $1.6 million in 2023, then decreased by 4.18% to $1.6 million in 2024, then slipped by 15.51% to $1.3 million in 2025, then rose by 6.75% to $1.4 million in 2026.
• Business Quant data shows ANIK's Depreciation & Amortization (CF) at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.